D-0133-2017 Class II Terminated
FDA drug recall D-0133-2017 was initiated by Sandoz Inc on Aug 24, 2016 and is designated Class II. Reason for recall: Defective Delivery System; reports of damaged product that may alter the predicted release of scopolamine following transdermal application. The recall status is terminated (terminated Jun 7, 2017). Affected quantity: 42,740 cartons (24 count carton from 7 total lots).
Recall details
- Product Type
- Drugs
- Report Date
- Nov 16, 2016
- Initiation Date
- Aug 24, 2016
- Termination Date
- Jun 7, 2017
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 42,740 cartons (24 count carton from 7 total lots)
Product description
Transderm Scop (scopolamine) Transdermal System, 1.5 mg, 24 patches Multi pack, Rx only, Marketed by Baxter Healthcare Cop/Novartis, Deerfield, IL 60015, Manufactured by:Alza Corporation, Vacaville, CA 95688 for Novartis Consumer Health Inc., Parsippany, NJ 07054
Reason for recall
Defective Delivery System; reports of damaged product that may alter the predicted release of scopolamine following transdermal application.
Distribution pattern
TN
Code information
NDC 10019-553-02 (24 ct. carton) and NDC 10019-553-88 (patch); Lot #'s FV5908 and FX1520 both with expiry 06/2018; GB4910 and GC4210 both with expiry 09/2018; GE1927 with expiry 12/2018; GF7017 with expiry 01/2019 and GH8065 with expiry 02/2019.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0133-2017
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026